Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 21Other hematologic neoplasm 14Plasma cell 3Myeloid 2Genitourinary 2CNS 2Head & Neck 1Dermatologic 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

fludarabine 63Cyclophosphamide 63venetoclax 57Azacitidine 52fludarabine phosphate 50Specimen Handling 44Whole-Body Irradiation 40ruxolitinib 37Mycophenolic Acid 37Tacrolimus 35Melphalan 32Busulfan 32Biopsy 32Cytarabine 31Stem Cell Transplantation 27Decitabine 27Granulocyte Colony-Stimulating Factor 21asciminib 19decitabine and cedazuridine drug combination 18Sirolimus 18Peripheral Blood Stem Cell Transplantation 18Injections 18Thiotepa 17Filgrastim 17nilotinib 15X-Rays 14Methotrexate 14Cyclosporine 14Imatinib Mesylate 13Magnetic Resonance Spectroscopy 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Methylprednisolone × Myeloid × 1 year × Clear all
NCT04216524 2026-04-14

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Myeloid

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT07525466 2026-04-13

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Beijing Tongren Hospital

Phase 1/2 Recruiting
25 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡